Sponsors (4)
The bill directs modest new federal resources to improve care, services, and research for sickle cell disease, trading a small increase in taxpayer cost and the risk of diverting limited public‑health funds and uncertain implementation unless future appropriations follow.
People with sickle cell disease: expanded program scope and increased funding could improve prevention and treatment of complications, giving patients greater access to supportive services and care.
Hospitals and clinics: new grant funding and cooperative agreements could provide resources to deliver or expand sickle cell services and programs at health centers and systems.
Public health and research community: increased authorization could support expanded research, surveillance, and public-health programs targeting heritable blood disorders, improving long-term knowledge and policy responses.
Taxpayers: federal spending would rise by about $3.75 million per year compared with prior authorization levels, increasing the federal cost burden.
Hospitals, clinics, and patients: expanding the program’s scope and funding could shift limited public-health resources toward sickle cell complications and away from other priorities if overall appropriations are constrained.
Patients and advocates: the bill largely states a congressional preference rather than guaranteeing action—its "sense of Congress" is non‑binding, so promised emphasis on research or programs may not materialize without future appropriations or implementing actions.
Based on analysis of 2 sections of legislative text.
Broadens CDC program to cover prevention and treatment of sickle cell complications, allows grants/cooperative agreements, and raises authorized funding to $8,205,000/yr for FY2025–2029.
Official title: Amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program.
Introduced February 26, 2025 by Tim Scott · Last progress February 26, 2025
Expands an existing HHS/CDC program that addresses sickle cell disease by broadening the program’s statutory language to explicitly include prevention and treatment of complications of sickle cell disease, allows grants and cooperative agreements in addition to contracts, and raises the authorized funding level to $8,205,000 per year for FY2025–2029. The bill also includes a non‑binding statement encouraging additional research into sickle cell disease and other heritable blood disorders.